4.4 Article

Benchmarking of laboratory evolved unspecific peroxygenases for the synthesis of human drug metabolites

Journal

TETRAHEDRON
Volume 75, Issue 13, Pages 1827-1831

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.tet.2019.02.013

Keywords

Unspecific peroxygenase; Human drug metabolites; Dextromethorphan; Tolbutamide; Naproxen; Heme access channel

Funding

  1. Spanish Government [BIO2016-79106-R-Lignolution, BI02016-76601-C3-1-R, CTQ2016-70138-R]
  2. CSIC [PIE-201580E042]
  3. Comunidad de Madrid Synergy CAM Project [Y2018/BIO-4738-EVOCHIMERA-CM]
  4. Ministry of Science, Innovation and Universities (Spain) [BES-2017-080040]
  5. CONACYT (Mexico)

Ask authors/readers for more resources

By mimicking the role of human liver P450 monooxygenases, fungal unspecific peroxygenases (UPOs) can perform a range of highly selective oxyfunctionalization reactions on pharmacological compounds, including O-dealkylations and hydroxylations, thereby simulating drug metabolism. Here we have benchmarked human drug metabolite (HDM) synthesis by several evolved UPO mutants, focusing on dextromethorphan, naproxen and tolbutamide. The HDM from dextromethorphan was prepared at the semi-preparative scale as a proof of production. The structural analysis of mutations involved in the synthesis of HDMs highlights the heme access channel as the main feature on which to focus when designing evolved UPOs. These variants are becoming emergent tools for the cost-effective synthesis of HDMs from next-generation drugs. (C) 2019 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available